SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, is now offering clients large molecule bioanalytical services at its laboratory in Wavre, Belgium.
The facility has invested in new and dedicated liquid chromatography-tandem mass spectrometry (LC/MS-MS) instruments and is currently validating internal methods within the laboratory, ensuring that services will be available by the end of 2017.
Bernard Jeanbaptiste, Bioanalysis Manager for SGS Belgium, said: “Our laboratory at Wavre has a rich history and expertise in small molecule analysis and the use of LC/MS-MS techniques. As a result, this investment is a natural progression of our capabilities, enabling us to serve the growing market for large molecule analysis and characterization. The investment will bring value to clients and support our current activities in large molecule bioanalysis across the global SGS network.”
SGS’s Wavre 8,400 sq m laboratory, on the outskirts of Brussels, provides a wide range of services to clients around the world, including method development and validation, analytical chemistry, microbiological testing, potency assays and cell line characterization.
With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
In Europe, the integrated SGS laboratory network contains several specialist service centers providing support for the testing requirements associated with small and large molecule development, including characterization of large molecules and bioanalysis.